Learning Objectives
Upon completion of this activity, participants should be able to:
- Analyze the long-term safety data of thrombopoietic agents being evaluated for the treatment of immune thrombocytopenia
- Evaluate how thrombopoietic agents may affect regulatory T-cell activity
- Integrate novel approaches for the treatment of antinuclear antibody-positive, refractory immune thrombocytopenia
- Compare the long-term benefits of combining rituximab and dexamethasone with dexamethasone alone in the first-line treatment of immune thrombocytopenia
- Pharmacists will be better able to provide accurate and appropriatre counsel as part of the treatment team
- Nurses will be better able to provide appropriate care and counsel for patients and their families
Topics covered include:
- Romiplostim in Nonsplenectomized Patients
- Long-term Romiplostim Safety and Efficacy
- Long-term Eltrombopag Safety and Efficacy
- Incidence of Eltrombopag-Associated Thromboembolic Events
- Thrombopoietic Agents and Regulatory T-Cells
- Anti-FcγRIII Inhibitory Monoclonal Antibodies
- Hydroxychloroquine in ANA-Positive ITP
- Rituximab Plus Dexamethasone vs Dexamethasone for ITP
- Predictors of Splenectomy Failure
- Concluding Remarks
Abstract